Business Context and Reporting Period
Company: OS Therapies Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2025
Reporting Period: Event date June 23, 2025; Inducement Period runs from June 20, 2025, to July 10, 2025.
Business Context: The Company is an emerging growth company focused on developing OST-HER2 for the prevention or delay of recurrent, fully resected, lung metastatic osteosarcoma. This filing details a Warrant Exercise Inducement to raise capital for regulatory and pre-commercial efforts.
Key Financial Metrics and Transaction Details
- Transaction Type: Warrant Exercise Inducement (Entry into Material Definitive Agreement).
- Existing Warrants: 1,574,288 shares at an exercise price of $1.12 per share.
- New Warrants Issued: 1,574,288 shares at an exercise price of $3.00 per share.
- Expected Gross Proceeds: Approximately $8 million (assuming full exercise of Existing Warrants).
- Transaction Costs: 5.0% cash fee to the Solicitation Agent based on gross proceeds, plus up to $15,000 for legal and other expenses.
- Use of Proceeds: U.S. and international regulatory and pre-commercial efforts for OST-HER2 and general corporate purposes.
- Liquidity/Debt: The filing text does not provide current cash balances, total debt, or liquidity ratios.
Material Changes and Terms
The Company entered into Inducement Letters with holders of Existing Warrants. Key terms include:
- Inducement Mechanism: Holders agree to exercise Existing Warrants for cash in exchange for New Warrants.
- New Warrant Terms:
- Immediately exercisable upon issuance.
- Five-year term.
- Subject to anti-dilution adjustments (exercise price reduces to the greater of the Dilutive Issuance Price or $1.00 per share).
- Forced exercise provision if the stock price exceeds 300% of the exercise price for 20 consecutive trading days.
- Beneficial ownership limitation of 4.99% (or 9.99% with notice).
- Registration: Resale of shares underlying Existing Warrants is registered. The Company must file a Form S-3 (or S-1) for New Warrant Shares within 30 days of closing.
Guidance, Outlook, and Risks
- Outlook: Proceeds are targeted at securing marketing authorizations for OST-HER2.
- Contingencies: The offering may be consummated in one or more closings. The Company reserves the right to extend, terminate, or suspend the Inducement Period at its sole discretion.
- Risks:
- The $8 million proceeds are contingent on the full exercise of Existing Warrants during the Inducement Period.
- Dilution risk exists if the Company issues equity at prices below the New Warrant exercise price ($3.00).
- Reliance on exemptions (Section 4(a)(2) and Rule 506(b)) for the sale of New Warrants.
Investor Verification Checklist
- Verify the actual number of Existing Warrants exercised and the final gross proceeds received by July 10, 2025.
- Confirm the effectiveness of the Resale Registration Statement (Form S-3 or S-1) for the New Warrant Shares.
- Monitor the Company's cash burn rate relative to the expected $8 million inflow to assess runway for OST-HER2 regulatory efforts.
- Review the specific terms of the Inducement Letters (Exhibit 10.1) and New Warrants (Exhibit 4.1) for any additional covenants or restrictions.
- Check for any subsequent equity issuances that might trigger the anti-dilution adjustment on the New Warrants.